is focused on improved kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread.Learn More
04.07.2014Deciphera Pharmaceuticals Announces Initiation of Phase 1 Cancer Trial for LY3009120 Pan-RAF Inhibitor Created and Developed in Collaboration with Eli Lilly
04.07.2014Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
03.17.2014Deciphera Pharmaceuticals Presents Preclinical Data on Rebastinib and DCC-3014 at AACR Tumor Microenvironment Conference
11.01.2013Deciphera announces the hiring of Michael DeSordi to the position of Vice President of Clinical Operations.